REGENXBIO Inc. Operating Cash Flow
REGENXBIO Inc. (RGNX) reported Operating Cash Flow of -$138.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- REGENXBIO Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$62.24M.
- REGENXBIO Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$76.19M, a 326.55% decline year-over-year.
- REGENXBIO Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$52.29M.
- REGENXBIO Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$55.96M.
- REGENXBIO Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$123.96M.
- REGENXBIO Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$173.13M.
- REGENXBIO Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$218.41M.
- REGENXBIO Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$207.49M, a 194.80% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$62.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$138.42M 10-Q · filed 2026-08-06 | -$190.71M derived: sum of 3 quarters · filed 2026-08-06 | -$246.67M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | -$76.19M 10-Q · filed 2026-05-14 | -$128.48M derived: sum of 2 quarters · filed 2026-05-14 | -$184.44M derived: sum of 3 quarters · filed 2026-05-14 | -$233.78M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$52.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$108.25M derived: sum of 2 quarters · filed 2026-03-05 | -$157.59M derived: sum of 3 quarters · filed 2026-08-06 | -$123.96M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | -$55.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$105.30M derived: sum of 2 quarters · filed 2026-08-06 | -$71.67M 10-Q · filed 2025-11-06 | -$103.30M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$49.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$15.71M 10-Q · filed 2026-08-06 | -$47.34M derived: sum of 3 quarters · filed 2026-08-06 | -$87.89M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $33.63M 10-Q · filed 2026-05-14 | $2.00M derived: sum of 2 quarters · filed 2026-05-14 | -$38.54M derived: sum of 3 quarters · filed 2026-05-14 | -$84.04M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | -$31.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$72.17M derived: sum of 2 quarters · filed 2026-03-05 | -$117.67M derived: sum of 3 quarters · filed 2026-03-05 | -$173.13M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | -$40.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$86.05M derived: sum of 2 quarters · filed 2025-11-06 | -$141.50M 10-Q · filed 2025-11-06 | -$182.26M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | -$45.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$100.95M 10-Q · filed 2025-08-07 | -$141.71M derived: sum of 3 quarters · filed 2025-08-07 | -$191.12M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | -$55.45M 10-Q · filed 2025-05-12 | -$96.22M derived: sum of 2 quarters · filed 2025-05-12 | -$145.62M derived: sum of 3 quarters · filed 2025-05-12 | -$192.94M derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | -$40.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$90.17M derived: sum of 2 quarters · filed 2025-03-13 | -$137.49M derived: sum of 3 quarters · filed 2025-03-13 | -$218.41M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | -$49.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$96.73M derived: sum of 2 quarters · filed 2024-11-06 | -$177.65M 10-Q · filed 2024-11-06 | -$217.02M derived: sum of 4 quarters · filed 2025-03-13 | |||
| 2023-06-30 | -$47.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$128.24M 10-Q · filed 2024-08-01 | -$167.61M derived: sum of 3 quarters · filed 2025-03-13 | -$218.07M derived: sum of 4 quarters · filed 2025-03-13 | |||
| 2023-03-31 | -$80.92M 10-Q · filed 2024-05-08 | -$120.29M derived: sum of 2 quarters · filed 2025-03-13 | -$170.75M derived: sum of 3 quarters · filed 2025-03-13 | -$232.50M derived: sum of 4 quarters · filed 2025-03-13 | |||
| 2022-12-31 | -$39.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$89.83M derived: sum of 2 quarters · filed 2025-03-13 | -$151.58M derived: sum of 3 quarters · filed 2025-03-13 | -$207.49M 10-K · filed 2025-03-13 | |||
| 2022-09-30 | -$50.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$112.20M derived: sum of 2 quarters · filed 2023-11-08 | -$168.12M 10-Q · filed 2023-11-08 | $173.38M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-06-30 | -$61.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$117.66M 10-Q · filed 2023-08-02 | $223.84M derived: sum of 3 quarters · filed 2024-02-27 | $181.33M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-03-31 | -$55.91M 10-Q · filed 2023-05-03 | $285.59M derived: sum of 2 quarters · filed 2024-02-27 | $243.08M derived: sum of 3 quarters · filed 2024-02-27 | $207.01M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2021-12-31 | $341.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $298.99M derived: sum of 2 quarters · filed 2024-02-27 | $262.92M derived: sum of 3 quarters · filed 2024-02-27 | $218.88M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | -$42.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$78.58M derived: sum of 2 quarters · filed 2022-11-03 | -$122.62M 10-Q · filed 2022-11-03 | -$107.36M 10-Q · filed 2021-11-02 | -$83.15M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-06-30 | -$36.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$80.12M 10-Q · filed 2022-08-03 | -$71.00M 10-Q · filed 2021-08-09 | -$40.65M derived: sum of 3 quarters · filed 2023-02-28 | -$77.11M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-03-31 | -$44.05M 10-Q · filed 2022-05-04 | -$41.13M 10-Q · filed 2021-05-05 | -$4.58M derived: sum of 2 quarters · filed 2023-02-28 | -$41.04M derived: sum of 3 quarters · filed 2023-02-28 | -$62.53M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2020-12-31 | $39.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $3.01M derived: sum of 2 quarters · filed 2023-02-28 | -$18.49M derived: sum of 3 quarters · filed 2023-02-28 | -$54.06M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | -$36.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$57.96M derived: sum of 2 quarters · filed 2021-11-02 | -$93.53M 10-Q · filed 2021-11-02 | -$119.03M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | -$21.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$57.07M 10-Q · filed 2021-08-09 | -$82.58M derived: sum of 3 quarters · filed 2022-03-01 | -$111.73M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | -$35.57M 10-Q · filed 2021-05-05 | -$61.08M derived: sum of 2 quarters · filed 2022-03-01 | -$90.23M derived: sum of 3 quarters · filed 2022-03-01 | -$113.98M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | -$25.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$54.66M derived: sum of 2 quarters · filed 2022-03-01 | -$78.41M derived: sum of 3 quarters · filed 2022-03-01 | -$107.70M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | -$29.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$52.90M derived: sum of 2 quarters · filed 2020-11-04 | -$82.20M 10-Q · filed 2020-11-04 | -$86.34M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-06-30 | -$23.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$53.05M 10-Q · filed 2020-08-06 | -$57.19M derived: sum of 3 quarters · filed 2021-03-01 | -$76.74M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-03-31 | -$29.30M 10-Q · filed 2020-05-07 | -$33.44M derived: sum of 2 quarters · filed 2021-03-01 | -$52.99M derived: sum of 3 quarters · filed 2021-03-01 | $17.22M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2018-12-31 | -$4.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$23.70M derived: sum of 2 quarters · filed 2021-03-01 | $46.51M derived: sum of 3 quarters · filed 2021-03-01 | $104.65M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | -$19.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $50.65M derived: sum of 2 quarters · filed 2019-11-05 | $108.79M 10-Q · filed 2019-11-05 | $94.96M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2018-06-30 | $70.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $128.34M 10-Q · filed 2019-08-07 | $114.52M derived: sum of 3 quarters · filed 2020-02-26 | $97.38M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2018-03-31 | $58.13M 10-Q · filed 2019-05-07 | $44.31M derived: sum of 2 quarters · filed 2020-02-26 | $27.17M derived: sum of 3 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | -$13.83M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$30.96M derived: sum of 2 quarters · filed 2020-02-26 | -$57.99M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | -$17.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$44.17M 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | -$27.03M 10-Q · filed 2018-08-08 | ||||||
| 2016-12-31 | -$48.56M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |